ArticleCureus2026
A Rare Case of Anti-HMGCR-Positive Immune-Mediated Necrotizing Myopathy Associated With Statin Use.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Statin-induced necrotizing autoimmune myopathy (SINAM) is a rare complication of chronic statin use that occurs in individuals aged 50 years and older, with statin exposure ranging from two months to 10 years. While common side effects of statins, such as self-limited myalgia and elevated creatine kinase (CK) levels or rhabdomyolysis, usually resolve with discontinuation, SINAM presents with more severe, persistent, and debilitating symptoms. We describe the case of an elderly man with no prior history of muscle weakness or statin-associated myopathy who presented with dysphagia and progressive weakness in both upper and lower extremities. He was initially diagnosed with statin-induced rhabdomyolysis and received supportive care. However, due to a lack of clinical improvement and based on an expanded literature review, SINAM was suspected. Empiric steroid therapy was initiated, and subsequent anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR) antibody testing returned positive, confirming the diagnosis. This case provides evidence on the use of steroid monotherapy in achieving disease remission. Additionally, it underscores the critical importance of maintaining a high index of suspicion and utilizing evidence-based approaches, especially when common investigative techniques yield no definitive cause. Early recognition and treatment of SINAM are essential to improve patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.